# Dabigatran Etexilate in Patients With Mechanical Heart Valves

> **NCT01452347** · PHASE2 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 328 (actual)

## Conditions studied

- Heart Valve Diseases

## Interventions

- **DRUG:** warfarin 1mg
- **DRUG:** dabigatran etexilate intermediate dose
- **DRUG:** dabigatran etexilate low dose
- **DRUG:** warfarin 5mg
- **DRUG:** dabigatran etexilate high dose
- **DRUG:** warfarin 3mg

## Key facts

- **NCT ID:** NCT01452347
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01452347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01452347, "Dabigatran Etexilate in Patients With Mechanical Heart Valves". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01452347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*